

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 4173

HOUGHTON ET AL.

Examiner: Benjamin J. Packard

APPLICATION NO: 10/530,618

FILED: FEBRUARY 23, 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED
RESISTANCE TO THERAPEUTIC AGENTS

MS: After Final

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450


NOTICE OF APPEAL
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on November 20, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 or payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



George R. Dohmann

Attorney for Applicants

Reg. No. 33,593

Phone No. (862) 778-7824

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080

Date: 2/10/09